News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion (ESPR): Up, Up, And Away?



5/18/2017 6:19:04 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Esperion Therapeutics (NASDAQ:ESPR) web site states that the company is a late-stage pharmaceutical company developing non-statin low density lipoprotein cholesterol-lowering (LDL-C) therapies. Three phase 3 studies are underway with nice preliminary results. LDLs are regarded as the harmful type of cholesterol when elevated levels are present. As described by the Center for Disease Control, LDL-C forms plaques that can build up in arteries and lead to heart disease and stroke. Bempedoic acid, its lead product, was confirmed by FDA in March 2017 to have an approval pathway and the company plans to submit its regulatory filings for manufacturing and NDA in the first half of 2019, pending readout of its global pivotal phase 3 trial expected in quarter two of 2018.

Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES